MONTREAL, QUEBEC -- (MARKET WIRE) -- May 02, 2007 -- Theratechnologies (TSX: TH) announced today that the last patient has completed 52 weeks of treatment in its first Phase 3 clinical study testing TH9507 in HIV-associated lipodystrophy. The Company expects to be in a position to present top-line, 52-week results at an appropriate venue later this year. This TH9507 Phase 3 trial is a multi-center, double-blind, randomized, placebo-controlled study conducted in 41 centers in the United States and Canada. The study is examining the safety and efficacy of a daily administration of 2 milligrams of TH9507 for a period of 26 weeks and long-term safety over a period of 52 weeks. A second, confirmatory Phase 3 study got underway in January 2007.
